CN108778333A - 严重社区获得性肺炎的治疗 - Google Patents

严重社区获得性肺炎的治疗 Download PDF

Info

Publication number
CN108778333A
CN108778333A CN201780017288.5A CN201780017288A CN108778333A CN 108778333 A CN108778333 A CN 108778333A CN 201780017288 A CN201780017288 A CN 201780017288A CN 108778333 A CN108778333 A CN 108778333A
Authority
CN
China
Prior art keywords
igm
equal
immunoglobulin
serum
immunoglobulin preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780017288.5A
Other languages
English (en)
Chinese (zh)
Inventor
P·朗戈尔
A·瓦滕贝格-德曼德
U·维珀曼
B·德尔肯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest AG
Original Assignee
Biotest AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest AG filed Critical Biotest AG
Publication of CN108778333A publication Critical patent/CN108778333A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780017288.5A 2016-03-14 2017-03-13 严重社区获得性肺炎的治疗 Pending CN108778333A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16160175.2 2016-03-14
EP16160175 2016-03-14
EP16185173.8 2016-08-22
EP16185173 2016-08-22
PCT/EP2017/055838 WO2017157850A1 (en) 2016-03-14 2017-03-13 Treatment of severe community acquired pneumonia

Publications (1)

Publication Number Publication Date
CN108778333A true CN108778333A (zh) 2018-11-09

Family

ID=58413057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780017288.5A Pending CN108778333A (zh) 2016-03-14 2017-03-13 严重社区获得性肺炎的治疗

Country Status (10)

Country Link
US (4) US20190076523A1 (https=)
EP (2) EP3851123A1 (https=)
JP (1) JP7041634B2 (https=)
CN (1) CN108778333A (https=)
AU (1) AU2017233923B2 (https=)
CA (1) CA3013849A1 (https=)
ES (1) ES2881201T3 (https=)
PL (1) PL3429622T3 (https=)
RU (1) RU2735680C2 (https=)
WO (1) WO2017157850A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112485448A (zh) * 2020-11-20 2021-03-12 浙江大学 Nmi蛋白作为生物靶标在制备成人社区获得性肺炎严重程度及预后评估试剂盒的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3747903A1 (en) 2019-06-07 2020-12-09 Biotest AG Method and kit for testing potency of immunoglobulin compositions
CA3195385A1 (en) 2020-11-19 2022-05-27 Biotest Ag Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071197A1 (en) * 2006-12-11 2008-06-19 Drugrecure Aps Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
CN102939111A (zh) * 2010-04-22 2013-02-20 生物测试股份公司 制备免疫球蛋白组合物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001319A1 (en) 1977-08-18 1979-04-04 Beecham Group Plc Process for the preparation of hydroxyphenyl hydantoin and of hydroxyphenyl glycine, and compounds thus obtained
DE2901822A1 (de) 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
US20130196310A1 (en) 2008-05-20 2013-08-01 Rapid Pathogen Screening, Inc. Method and Device for Combined Detection of Viral and Bacterial Infections
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
RU2470664C2 (ru) * 2010-08-23 2012-12-27 Андрей Германович Лютов Способ получения иммуноглобулина для внутривенного введения, обогащенного иммуноглобулином м, и препарат, полученный этим способом
ES2751976T3 (es) 2012-03-09 2020-04-02 Csl Behring Ag Composiciones que comprenden inmunoglobulinas de tipo secretor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071197A1 (en) * 2006-12-11 2008-06-19 Drugrecure Aps Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
CN102939111A (zh) * 2010-04-22 2013-02-20 生物测试股份公司 制备免疫球蛋白组合物的方法
CN102939107A (zh) * 2010-04-22 2013-02-20 生物测试股份公司 抗体制剂

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MARI C. DE LA TORRE等: ""Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia"", 《RESPIRATORY MEDICINE》 *
PEDRO P. ESPANA等: ""Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia"", 《JOURNAL OF INFECTION》 *
TOBIAS WELTE等: ""Concept for a study design in patients with severe community-acquired pneumonia- A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study"", 《RESPIRATORY MEDICINE》 *
刘晓明主编: "《实用临床内科诊疗学》", 31 January 2015, 西安：西安交通大学出版社 *
秋甫等主编: "《内科临床经验荟萃》", 28 February 2012, 北京：金盾出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112485448A (zh) * 2020-11-20 2021-03-12 浙江大学 Nmi蛋白作为生物靶标在制备成人社区获得性肺炎严重程度及预后评估试剂盒的应用
CN112485448B (zh) * 2020-11-20 2021-08-24 浙江大学 Nmi蛋白作为生物靶标在制备成人社区获得性肺炎严重程度及预后评估试剂盒的应用

Also Published As

Publication number Publication date
AU2017233923A1 (en) 2018-08-09
US12186391B2 (en) 2025-01-07
RU2018135290A3 (https=) 2020-04-16
US11517621B2 (en) 2022-12-06
US20200268881A1 (en) 2020-08-27
RU2735680C2 (ru) 2020-11-05
EP3429622B1 (en) 2021-04-21
WO2017157850A1 (en) 2017-09-21
US20210162043A1 (en) 2021-06-03
JP7041634B2 (ja) 2022-03-24
RU2018135290A (ru) 2020-04-15
US20190076523A1 (en) 2019-03-14
US20230241210A1 (en) 2023-08-03
US10918715B2 (en) 2021-02-16
EP3851123A1 (en) 2021-07-21
CA3013849A1 (en) 2017-09-21
ES2881201T3 (es) 2021-11-29
PL3429622T3 (pl) 2021-11-02
EP3429622A1 (en) 2019-01-23
AU2017233923B2 (en) 2023-10-12
JP2019508458A (ja) 2019-03-28

Similar Documents

Publication Publication Date Title
US12186391B2 (en) Treatment of severe community acquired pneumonia
JP2016512263A (ja) 自己免疫性障害の処置におけるレボセチリジン及びモンテルカストの使用
TW201718014A (zh) C5抑制劑於移植相關微血管病之用途
WO2018053029A1 (en) Methods for treating pulmonary disease using inter-alpha inhibitor proteins
JP2022176345A (ja) 敗血症の処置のためのチモシンαの使用
HK1222818A1 (zh) 左西替利嗪和孟鲁司特在治疗创伤性损伤中的用途
US20230151107A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
Kim et al. A case of acute cerebral aspergillosis complicating influenza A/H1N1pdm 2009
WO2021260692A1 (en) Compositions and methods for treating infectious disease caused by coronavirus
TW202423978A (zh) 急性呼吸衰竭之治療
HK40046908A (en) Treatment of severe community acquired pneumonia
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
WO2021207697A1 (en) Treatment of acute lung injury
HK1259313A1 (en) Treatment of severe community acquired pneumonia
HK1259313B (en) Treatment of severe community acquired pneumonia
JP2023541921A (ja) Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果
CA3237246A1 (en) Administration of c5-binding proteins
Gharebaghi et al. Intravenous Immunoglobulin Gamma for Severe Cases of Coronavirus Disease of 2019: A Randomized Placebo-Controlled Double-Blinded Clinical Trial
KR20220010456A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
HK40128284A (zh) 急性呼吸衰竭的治疗
TW201929895A (zh) 使用間-α抑制蛋白治療肺病之方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination